试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-14
Effectiveness of Corticosteroid vs. Ketorolac Shoulder Injections: A Prospective Double-Blinded Randomized Trial
编号:NCT04115644登记状态:提前终止企业 / 申办者:Michael Khazzam
药物 / 成分:Ketorolac、Marcaine (placebo)、Kenalog
登记的停止原因(原文):Covid-19 and we failed to submit annual report for 2017 and 2018
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-14
Perampanel in Focal Status Epilepticus
编号:NCT04309721登记状态:提前终止企业 / 申办者:Assistance Publique - Hôpitaux de Paris
药物 / 成分:Perampanel、Placebo
登记的停止原因(原文):Lack of inclusion
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-14
A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer
编号:NCT04809805登记状态:提前终止企业 / 申办者:Bayer
药物 / 成分:BAY2666605
登记的停止原因(原文):Due to the high probability of not achieving a therapeutic window and lack of evidence of sufficient clinical benefit.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-14
A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults
编号:NCT04900038登记状态:提前终止企业 / 申办者:ViiV Healthcare
药物 / 成分:GSK3640254、Dolutegravir、Lamivudine capsules、Lamivudine tablets
登记的停止原因(原文):Company decision to stop compound development. The decision was not based on any safety or efficacy concerns. It reflected the company strategy for portfolio progression.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-14
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants
编号:NCT05099822登记状态:提前终止企业 / 申办者:Celgene
药物 / 成分:CC-97489、Placebo
登记的停止原因(原文):Business objectives changed.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-13
Variability in Response to Non-steroidal Anti-inflammatory Drugs
编号:NCT02502006登记状态:提前终止企业 / 申办者:University of Pennsylvania
药物 / 成分:Celecoxib、Naproxen、Placebo
登记的停止原因(原文):Funding was not available to complete enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-13
Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure
编号:NCT04071626登记状态:提前终止企业 / 申办者:University Hospitals Cleveland Medical Center
药物 / 成分:Ertugliflozin 5 mg、Placebo oral tablet
登记的停止原因(原文):Lack of enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-13
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
编号:NCT04549363登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:Belantamab mafodotin
登记的停止原因(原文):The study has been terminated for reasons pertaining to feasibility
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-13
Assessing the Effects of Sublingual Sufentanil 30 µg on Postoperative Recovery
编号:NCT04561375登记状态:提前终止企业 / 申办者:The Cleveland Clinic
药物 / 成分:Sufentanil、Fentanyl
登记的停止原因(原文):For practical reasons of slow enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-13
Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma
编号:NCT04663126登记状态:提前终止企业 / 申办者:John O. Prior
药物 / 成分:Tc-99m tilmanocept
登记的停止原因(原文):after inclusion of 5 patients, tracer had low uptake (kidney/liver)
查看官方原始记录 ↗